First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Christoph SchliemannMirjam GerwingHauke Sebastian HeinzowSaliha HarrachChristian SchwöppeMoritz WildgruberAnna A HansmeierLinus AngenendtAndrew F BerdelUrsula StalmannBjörna BerningKarsten Kratz-AlbersKristina Middelberg-BispingStefanie WiebeJörn C AlbringChristian WilmsWolfgang HartmannEva WardelmannTobias KrählingWalter HeindelJoachim GerßEike BormannHartmut SchmidtGeorg LenzTorsten KesslerRolf M MestersWolfgang E BerdelPublished in: Cancers (2020)
tTF-NGR is safely applicable with this regimen. Imaging showed selective reduction of tumor blood flow and intratumoral hemorrhage and necrosis.